Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a rare, progressive neurodegenerative disorder characterized by the abnormal accumulation of tau protein in certain brain regions, leading to widespread neuronal loss. First described by Steele, Richardson, and Olszewski in 1964, PSP belongs to the group of “Parkinson-plus” syndromes because its symptoms—such as rigidity, bradykinesia, and postural instability—overlap with Parkinson’s disease but have distinct clinical and pathological features (e.g., vertical gaze palsy and poor response to levodopa) ncbi.nlm.nih.goven.wikipedia.org. Pathologically, PSP manifests with neurofibrillary tangles in neurons and glia, especially in the basal ganglia, brainstem, and cerebellum, leading to progressive impairment in movement control, balance, eye movements, speech, swallowing, and cognition en.wikipedia.org. Onset typically occurs between ages 50 and 70, with a slight male predominance. The course of PSP is relentlessly progressive, with median survival of 5–7 years after diagnosis.

Progressive Supranuclear Palsy (PSP) is a rare, late-onset neurodegenerative disorder characterized by the accumulation of abnormal tau protein in specific brain regions. It leads to steadily worsening control of eye movements, balance, posture, mobility, speech and swallowing, as well as cognitive and emotional changes. Onset typically occurs between ages 60 and 70, and without a cure, life expectancy averages 7–10 years after diagnosis en.wikipedia.org. Early signs include slowed movement (bradykinesia), unexplained falls, particularly backward, and difficulty looking downwards despite intact ocular muscles. Magnetic resonance imaging often reveals midbrain atrophy with a preserved pons (“hummingbird sign”), aiding diagnosis en.wikipedia.orgpmc.ncbi.nlm.nih.gov.

---

Types of Progressive Supranuclear Palsy

PSP presents in several clinical phenotypes, reflecting variation in which brain regions are most affected. Each type shares the same underlying tauopathy but differs in early symptom predominance:

1. Richardson’s Syndrome (PSP-RS)
The classic form, featuring early, unexplained backward falls, axial rigidity, and vertical gaze palsy. Cognitive slowing and frontal executive dysfunction also occur early ncbi.nlm.nih.gov.

2. PSP-Parkinsonism (PSP-P)
Resembles Parkinson’s disease with asymmetric limb rigidity and tremor, and shows a milder response to levodopa. Falls and vertical gaze palsy appear later in the course en.wikipedia.org.

3. PSP-Frontal (PSP-F)
Presents initially with behavioral changes, apathy, disinhibition, or executive dysfunction. Motor and ocular symptoms develop later en.wikipedia.org.

4. PSP-Progressive Gait Freezing (PSP-PAGF)
Marked by early-onset gait freezing without significant limb rigidity. Ocular movement and cognitive changes follow later in the disease en.wikipedia.org.

5. PSP-Corticobasal Syndrome (PSP-CBS)
Shows asymmetric limb apraxia, cortical sensory loss, and alien limb phenomenon. Vertical gaze palsy and axial rigidity develop subsequently en.wikipedia.org.

6. PSP-Speech/Language (PSP-SL)
Presents with primary progressive aphasia, including nonfluent speech and word-finding difficulty. Eye movement abnormalities and parkinsonism follow en.wikipedia.org.

7. PSP-Cerebellar (PSP-C)
Rare phenotype with prominent early cerebellar ataxia and dysarthria. Vertical gaze palsy and rigidity appear as the disease evolves en.wikipedia.org.

---

Causes and Risk Factors

While the exact cause of PSP remains unknown, multiple genetic, molecular, and environmental factors contribute to disease development. Each proposed cause below is supported by clinical or pathological evidence.

1. Tau Protein Misfolding
   PSP is driven by abnormal accumulation of four‐repeat tau isoforms forming neurofibrillary tangles in neurons and glia, disrupting cellular transport and leading to cell death en.wikipedia.org.

2. MAPT H1 Haplotype
   A specific variant (H1) of the MAPT gene on chromosome 17 increases PSP risk by promoting tau aggregation; nearly 94% of PSP patients carry two H1 copies en.wikipedia.org.

3. Age
   Incidence rises with age; most cases appear between 50 and 70 years, likely reflecting cumulative tau pathology and reduced cellular repair mechanisms ncbi.nlm.nih.gov.

4. Male Sex
   Men are approximately 1.3 times more likely to develop PSP, suggesting sex‐linked genetic or hormonal influences on tau metabolism ncbi.nlm.nih.gov.

5. Oxidative Stress
   Elevated reactive oxygen species damage neurons; PSP brain tissue shows increased markers of oxidative injury, possibly triggering tau hyperphosphorylation ncbi.nlm.nih.gov.

6. Mitochondrial Dysfunction
   Impaired mitochondrial respiration in PSP leads to energy failure and neuronal vulnerability; mitochondrial DNA variants have been implicated ncbi.nlm.nih.gov.

7. Neuroinflammation
   Activated microglia and elevated proinflammatory cytokines are observed in PSP brains, suggesting inflammation exacerbates tau pathology ncbi.nlm.nih.gov.

8. Prion‐like Tau Propagation
   Pathological tau may spread cell‐to‐cell in a prion‐like fashion, seeding further tau aggregation across brain regions en.wikipedia.org.

9. Head Trauma
   Epidemiological studies link repetitive head injuries to parkinsonian tauopathies, possibly by accelerating tau hyperphosphorylation ojrd.biomedcentral.com.

10. Environmental Toxins
    Exposure to certain metals (e.g., manganese) and pesticides may increase PSP risk by promoting oxidative stress and tau pathology ncbi.nlm.nih.gov.

11. Vascular Dysfunction
    Small‐vessel cerebrovascular disease may interact with tau pathology, leading to vascular PSP variants characterized by multiple infarcts en.wikipedia.org.

12. Lipid Dysregulation
    Altered cholesterol and sphingolipid metabolism in PSP may affect membrane tau binding and aggregation ncbi.nlm.nih.gov.

13. Autophagy Impairment
    Reduced clearance of abnormal proteins via the autophagy–lysosomal pathway leads to tau accumulation ncbi.nlm.nih.gov.

14. Endoplasmic Reticulum Stress
    Disruption of protein folding in the ER triggers the unfolded protein response, contributing to tau aggregation ncbi.nlm.nih.gov.

15. Genetic Variants Beyond MAPT
    Variants in STX6, EIF2AK3, and MOBP genes have been linked to PSP risk, highlighting multiple molecular pathways en.wikipedia.org.

16. Abnormal Protein Phosphatases
    Reduced activity of phosphatases (e.g., PP2A) leads to hyperphosphorylation of tau and its aggregation ncbi.nlm.nih.gov.

17. Synaptic Dysfunction
    Loss of synaptic proteins and dendritic spines in PSP disrupts neuronal communication, exacerbating neurodegeneration ncbi.nlm.nih.gov.

18. Genetic Susceptibility Interactions
    Combinations of genetic risk factors (e.g., MAPT H1 with EIF2AK3 variants) may synergistically increase PSP likelihood en.wikipedia.org.

19. Sex Hormone Imbalance
    Lower estrogen levels in aging men may reduce tau clearance, potentially contributing to male predominance ncbi.nlm.nih.gov.

20. Unknown Sporadic Factors
    Over 90% of PSP cases are sporadic, indicating that additional, as yet unidentified, environmental or epigenetic factors play roles en.wikipedia.org.

---

Symptoms of PSP

Below are twenty common symptoms of PSP, each reflecting dysfunction in the affected brain regions.

1. Early Postural Instability and Falls
   Unexplained backward falls often occur within the first year, due to axial rigidity and impaired balance mayoclinic.org.

2. Vertical Gaze Palsy
   Difficulty moving the eyes up or down, especially downward gaze, is a hallmark and often the first ocular sign ninds.nih.gov.

3. Axial Rigidity
   Stiffness of neck and trunk impairs posture and gait, contributing to falls ncbi.nlm.nih.gov.

4. Bradykinesia
   Generalized slowness of movement affecting daily activities and reaction times ncbi.nlm.nih.gov.

5. Dysphagia
   Difficulty swallowing leads to choking risk and weight loss; arises from brainstem involvement my.clevelandclinic.org.

6. Dysarthria
   Slurred, slow, or soft speech due to muscle control loss in face and larynx my.clevelandclinic.org.

7. Pseudobulbar Affect
   Involuntary emotional lability—uncontrolled laughing or crying—due to corticobulbar pathway damage ncbi.nlm.nih.gov.

8. Neck Dystonia (“Collar” Posture)
   Sustained contraction of neck muscles causes backward head thrust, worsening balance ncbi.nlm.nih.gov.

9. Supranuclear Ophthalmoplegia
   Loss of voluntary eye movements despite intact reflex eye movements, confirming nuclear vs supranuclear lesion ncbi.nlm.nih.gov.

10. Axial Bradykinesia
    Slowness of trunk movements further compromises postural adjustments ncbi.nlm.nih.gov.

11. Freezing of Gait
    Sudden inability to initiate steps, especially in tight spaces, reflecting advanced gait circuit impairment ncbi.nlm.nih.gov.

12. Cognitive Executive Dysfunction
    Slowed thinking, impaired planning, and difficulty multitasking due to frontal lobe involvement ncbi.nlm.nih.gov.

13. Personality Changes
    Apathy, disinhibition, or emotional blunting often emerge early in PSP‐F phenotype ncbi.nlm.nih.gov.

14. Sleep Disturbances
    Insomnia or fragmented sleep arise from brainstem reticular formation involvement ncbi.nlm.nih.gov.

15. Dementia‐Like Decline
    Progressive memory loss and cognitive decline, particularly affecting attention and abstraction ncbi.nlm.nih.gov.

16. Buccolinguolingual Apraxia
    Difficulty coordinating mouth and tongue movements for speech and swallowing ncbi.nlm.nih.gov.

17. Impaired Vertical Smooth Pursuit
    Loss of the smooth tracking eye movement when following moving objects ninds.nih.gov.

18. Neck Extensor Weakness (“Head Drop”)
    Weakness of neck extensors leads to head tilting forward, worsening swallowing and breathing ncbi.nlm.nih.gov.

19. Anhedonia and Depression
    Low mood and reduced pleasure due to involvement of limbic circuits ncbi.nlm.nih.gov.

20. Sensory Changes
    Mild reduced vibration or proprioception in limbs due to secondary degeneration of sensory pathways ncbi.nlm.nih.gov.

---

Diagnostic Tests for PSP

Accurate diagnosis of PSP relies on detailed clinical examination and supportive tests. Below are 40 diagnostic modalities, grouped by category.

A. Physical Examination

1. Neurological Gait Assessment
   Observing patient walking to identify early backward falls, freezing, and shuffling gait.

2. Ocular Motility Testing
   Clinician guides eyes through ranges to detect supranuclear gaze palsy.

3. Rigidity Evaluation
   Passive limb and neck movement to assess axial versus appendicular stiffness.

4. Postural Reflex Testing
   Pull‐test to evaluate retropulsion and postural instability.

5. Speech and Swallow Observation
   Assess voice volume, articulation, and swallowing safety.

6. Facial Expression Examination
   Check for hypomimia (masked face) and emotional expression.

7. Strength Testing
   Manual muscle testing to rule out weakness as cause of falls.

8. Sensory Screening
   Basic vibration and proprioception checks to exclude primary sensory neuropathies.

B. Manual Tests

9. Pull‐Test
   Sudden backward tug on shoulders to elicit postural instability.

10. Timed Up and Go (TUG) Test
    Measures time to stand, walk 3 meters, turn, and return, quantifying mobility.

11. Nine‐Hole Peg Test
    Evaluates fine motor dexterity by having patients place pegs in holes.

12. Finger Tapping Test
    Assesses bradykinesia by counting alternate finger taps per time unit.

13. Cognitive Mental Status Exam
    Includes clock‐drawing and verbal fluency to screen executive function.

14. Frontal Assessment Battery (FAB)
    Six tasks to evaluate frontal lobe functions such as motor programming.

15. Mini‐BESTest
    Assesses balance control under various conditions.

16. MoCA (Montreal Cognitive Assessment)
    Sensitive screening for mild cognitive impairment in PSP.

C. Laboratory & Pathological Tests

17. Cerebrospinal Fluid (CSF) Tau and NfL Levels
    Elevated neurofilament light chain and altered tau ratios support PSP en.wikipedia.org.

18. Blood Serum Tau Isoform Analysis
    Research tool measuring tau fragments; not yet routine.

19. Genetic Testing for MAPT H1/H2 Haplotype
    Identifies high‐risk MAPT variants.

20. Inflammatory Marker Panel
    Assess cytokines (e.g., IL-6, TNF-α) indicating neuroinflammation.

21. Mitochondrial DNA Sequencing
    Investigates mitochondrial dysfunction contributions.

22. Autoimmune Workup
    Excludes autoimmune encephalitis mimicking PSP.

23. Vitamin B12 and Thyroid Function Tests
    Rule out metabolic mimics of parkinsonism.

24. Urine Heavy Metal Screen
    Detects environmental toxins linked to tauopathies.

D. Electrodiagnostic Tests

25. Electrooculography (EOG)
    Quantifies eye movement velocities to confirm supranuclear gaze deficits.

26. Electromyography (EMG)
    Rules out neuromuscular disorders in dysarthria and dysphagia.

27. Nerve Conduction Studies (NCS)
    Excludes peripheral neuropathy as cause of gait disturbance.

28. Transcranial Magnetic Stimulation (TMS)
    Probes cortical excitability and connectivity in motor pathways.

29. Surface EMG during Swallowing
    Evaluates timing and pattern of muscle activation in dysphagia.

30. Polysomnography
    Studies sleep architecture to detect REM sleep behavior disorder.

31. Event‐Related Potentials (ERP)
    Assesses cognitive processing speed and integrity.

32. Electroencephalography (EEG)
    Excludes seizure activity and monitors cortical dysfunction.

E. Imaging Tests

33. Magnetic Resonance Imaging (MRI)
    Midbrain atrophy with “hummingbird” sign and preserved pons is characteristic en.wikipedia.org.

34. Diffusion Tensor Imaging (DTI)
    Detects reduced fractional anisotropy in superior cerebellar peduncles and corpus callosum en.wikipedia.org.

35. Positron Emission Tomography (PET)
    Tau‐specific tracers reveal regional tau burden; FDG‐PET shows hypometabolism in midbrain and frontal cortex.

36. Single-Photon Emission Computed Tomography (SPECT)
    Dopamine transporter imaging distinguishes PSP from Parkinson’s disease by showing symmetric striatal uptake reduction.

37. Volumetric MRI Analysis
    Quantifies midbrain–pons ratio to support early PSP diagnosis.

38. Ultrasound of Substantia Nigra
    Hyperechogenicity may differ between PSP and PD.

39. Voxel‐Based Morphometry (VBM)
    Research tool mapping grey matter loss in PSP phenotypes.

40. Magnetic Resonance Spectroscopy (MRS)
    Measures neurotransmitter and metabolite changes in affected regions.

Non-Pharmacological Treatments

Non-drug therapies are essential in PSP, addressing mobility, function, mood and quality of life. Early, multidisciplinary intervention maximizes benefits pmc.ncbi.nlm.nih.gov.

A. Physiotherapy & Electrotherapy Therapies

1. Gait Training
   Description: Structured walking exercises under therapist supervision, often with parallel bars.
   Purpose: Improve step symmetry, reduce fall risk.
   Mechanism: Repetitive practice enhances neural pathways for locomotion and balance physio-pedia.com.

2. Balance and Transfer Training
   Description: Practice of sit-to-stand, turning, and weight shifts.
   Purpose: Enhance postural control during transfers.
   Mechanism: Stimulates proprioceptive feedback and cerebellar networks to maintain upright posture physio-pedia.com.

3. Weighted Ankle Gait Exercises
   Description: Walking with light ankle weights (0.5–1 kg).
   Purpose: Strengthen lower limb muscles, improve stride length.
   Mechanism: Increases muscle activation and joint proprioception researchgate.net.

4. Visual Tracking Exercises
   Description: Eye movement tasks following targets horizontally and vertically.
   Purpose: Address supranuclear gaze palsy, especially downward gaze.
   Mechanism: Encourages cortical–brainstem–oculomotor integration to compensate eye movement deficits mayoclinic.org.

5. Functional Electrical Stimulation (FES)
   Description: Mild electrical pulses to dorsiflexors during gait.
   Purpose: Prevent foot drop and improve leg swing.
   Mechanism: Directly activates motor neurons, reinforcing central pattern generators physio-pedia.com.

6. Transcranial Magnetic Stimulation (TMS)
   Description: Non-invasive magnetic pulses to motor cortex.
   Purpose: Modulate cortical excitability, potentially improving rigidity.
   Mechanism: Alters synaptic plasticity through long-term potentiation/depression pmc.ncbi.nlm.nih.gov.

7. Aquatic Therapy
   Description: Exercises in warm water pools.
   Purpose: Facilitate movement with buoyancy, reduce fall risk.
   Mechanism: Water resistance provides graded strengthening; hydrostatic pressure aids postural stability physio-pedia.com.

8. Constraint-Induced Movement Therapy
   Description: Restricting stronger limb to encourage use of weaker side.
   Purpose: Counteract learned non-use in upper limbs.
   Mechanism: Promotes cortical reorganization by forcing use-dependent plasticity pmc.ncbi.nlm.nih.gov.

9. Neck Rigidity Stretching
   Description: Manual and active stretching of cervical muscles.
   Purpose: Reduce neck stiffness, improve head control.
   Mechanism: Length-tension normalization and mechanoreceptor adaptation researchgate.net.

10. Postural Awareness Training
    Description: Mirror-guided correction of posture during standing/seating.
    Purpose: Enhance conscious self-correction of stooped posture.
    Mechanism: Visual feedback integrates with vestibular inputs to recalibrate posture mayoclinic.org.

11. Vestibular Rehabilitation
    Description: Head movement exercises to provoke and adapt to vestibular stimuli.
    Purpose: Improve balance, reduce dizziness.
    Mechanism: Enhances central compensation for vestibular deficits through habituation pmc.ncbi.nlm.nih.gov.

12. Sensory Re-education
    Description: Textured surface walking and varied sensory input tasks.
    Purpose: Boost proprioceptive awareness in feet and ankles.
    Mechanism: Stimulates mechanoreceptors to strengthen somatosensory pathways physio-pedia.com.

13. Robotic-Assisted Gait Training
    Description: Body-weight support treadmill with robotic guidance.
    Purpose: Facilitate safe repetitive gait patterns.
    Mechanism: Provides consistent sensory cues, enhancing spinal locomotor circuits pmc.ncbi.nlm.nih.gov.

14. Mirror Therapy
    Description: Reflecting movements of unaffected limb to “trick” the brain.
    Purpose: Reduce motor neglect and improve symmetry.
    Mechanism: Visual illusion promotes mirror neuron system activation pmc.ncbi.nlm.nih.gov.

15. Rhythmic Auditory Stimulation
    Description: Metronome- or music-guided stepping exercises.
    Purpose: Enhance timing and rhythm of gait.
    Mechanism: Auditory cues entrain motor timing networks in the basal ganglia journals.sagepub.com.

B.  Exercise Therapies

1. Aerobic Cycling
   Description: Low-resistance stationary cycling for 20–30 minutes.
   Purpose: Improve cardiovascular health, reduce fatigue.
   Mechanism: Elevates neurotrophic factors (e.g., BDNF) supporting neuronal survival mdpi.com.

2. Seated Yoga Poses
   Description: Modified gentle stretches and breathing exercises.
   Purpose: Enhance flexibility, reduce stress.
   Mechanism: Activates parasympathetic system, lowering muscle tone and anxiety mayoclinic.org.

3. Tai Chi
   Description: Slow, flowing weight-shifting movements.
   Purpose: Improve balance, proprioception and mindfulness.
   Mechanism: Combines vestibular, visual and proprioceptive training with cognitive focus physio-pedia.com.

4. Core Stability Exercises
   Description: Seated or standing trunk strengthening (e.g., pelvic tilts).
   Purpose: Stabilize core to support posture and transfers.
   Mechanism: Enhances neuromuscular control of axial muscles pmc.ncbi.nlm.nih.gov.

5. Resistance Band Strengthening
   Description: Targeted upper and lower limb exercises with elastic bands.
   Purpose: Maintain muscle mass, reduce weakness.
   Mechanism: Progressive overload stimulates muscle hypertrophy and neural drive physio-pedia.com.

C. Mind-Body Therapies

1. Mindfulness Meditation
   Description: Guided breathing and sensory awareness sessions.
   Purpose: Reduce anxiety, improve coping with progressive loss of function.
   Mechanism: Alters prefrontal–limbic connections, enhancing stress resilience mayoclinic.org.

2. Guided Imagery
   Description: Therapist-led visualization of successful movements.
   Purpose: Reinforce motor patterns and self-efficacy.
   Mechanism: Activates motor planning areas without physical execution pmc.ncbi.nlm.nih.gov.

3. Music Therapy
   Description: Rhythmic and melodic exercises to facilitate movement.
   Purpose: Enhance gait and mood through auditory stimulation.
   Mechanism: Engages basal ganglia–cortical loops for movement and emotional regulation journals.sagepub.com.

4. Art Therapy
   Description: Painting or sculpting to express emotions.
   Purpose: Support cognitive function and emotional health.
   Mechanism: Stimulates frontal and parietal regions involved in planning and creativity pmc.ncbi.nlm.nih.gov.

5. Biofeedback
   Description: Visual feedback of muscle or heart rate activity.
   Purpose: Teach self-regulation of muscle tension and stress.
   Mechanism: Strengthens mind-body connections via real-time physiologic monitoring mayoclinic.org.

D. Educational Self-Management Strategies

1. Online PSP Education Modules
   Description: Structured, interactive courses on disease and safety.
   Purpose: Empower patients/caregivers with knowledge to manage daily challenges.
   Mechanism: Increases treatment adherence through informed decision-making pmc.ncbi.nlm.nih.gov.

2. Energy Conservation Training
   Description: Techniques for pacing activities and using assistive devices.
   Purpose: Prevent fatigue and maintain independence.
   Mechanism: Optimizes energy use by balancing activity/rest cycles mayoclinic.org.

3. Home Safety Assessments
   Description: Occupational therapist–led evaluations with adaptations (grab bars, lighting).
   Purpose: Reduce fall risk, facilitate safe mobility.
   Mechanism: Modifies environment to align with functional capacity nhs.uk.

4. Swallowing and Speech Workshops
   Description: Group classes teaching compensatory swallowing and communication techniques.
   Purpose: Maintain nutrition, reduce aspiration risk, and support speech.
   Mechanism: Reinforces alternative motor patterns for oropharyngeal function mayoclinic.org.

5. Caregiver Skill-Building Sessions
   Description: Hands-on training in transfer techniques, toileting, and behavioral strategies.
   Purpose: Enhance safety and reduce caregiver burden.
   Mechanism: Transfers best practices via adult learning principles and supervised practice pmc.ncbi.nlm.nih.gov.

---

Evidence-Based Drugs

While no disease-modifying therapy exists, various medications address PSP symptoms. Each is given as dosages for typical adult patients; adjust for renal/hepatic function as needed.

1. Levodopa/Carbidopa (100 mg/25 mg TID) – Dopaminergic agent. Modest improvement in bradykinesia and rigidity; poor response in most PSP patients en.wikipedia.org. Side effects: nausea, orthostatic hypotension.

2. Amantadine (100 mg BID) – NMDA antagonist. May reduce rigidity and fatigue. Side effects: livedo reticularis, edema en.wikipedia.org.

3. Baclofen (10 mg TID) – GABA-B agonist. Relieves spasticity. Side effects: sedation, weakness.

4. Tizanidine (2 mg TID) – α2-adrenergic agonist. Muscle relaxant for rigidity. Side effects: hypotension, dry mouth.

5. Botulinum Toxin A (20–50 U injection) – Neuromuscular blocker. Treats blepharospasm and cervical dystonia. Side effects: local weakness.

6. Trihexyphenidyl (1 mg TID) – Anticholinergic. Eases dystonic postures. Side effects: dry mouth, cognitive impairment.

7. Fluoxetine (20 mg daily) – SSRI. May alleviate depression and pseudobulbar affect. Side effects: insomnia, GI upset.

8. Sertraline (50 mg daily) – SSRI. Alternative for mood stabilization; similar side effects to fluoxetine.

9. Venlafaxine (37.5 mg daily) – SNRI. Addresses depression and anxiety. Side effects: hypertension, sweating.

10. Rivastigmine (4.6 mg/24 h patch) – Cholinesterase inhibitor. May help cognitive slowing. Side effects: nausea, bradycardia.

11. Memantine (10 mg BID) – NMDA antagonist. Off-label for cognitive symptoms. Side effects: dizziness, headache.

12. Riluzole (50 mg BID) – Glutamate modulator. Investigational for neuroprotection. Side effects: liver enzyme elevation.

13. Tideglusib (1000 mg daily) – GSK-3 inhibitor. Experimental tau-aggregation blocker in trials. Side effects: GI upset.

14. Davunetide (AL-108) (30 mg intranasal) – Microtubule stabilizer. Clinical trial phase II. Side effects: nasal irritation.

15. Nilotinib (150 mg daily) – c-Abl inhibitor. Investigational autophagy enhancer; small pilot studies only.

16. N‐acetylcysteine (600 mg BID) – Antioxidant. Off-label; minimal evidence. Side effects: rash.

17. Modafinil (100 mg daily) – Wake-promoting agent. Treats daytime somnolence. Side effects: headache, anxiety.

18. Methylphenidate (5 mg BID) – Central stimulant. May boost alertness. Side effects: increased heart rate, insomnia.

19. Dextromethorphan/Quinidine (20 mg/10 mg BID) – NMDA antagonist/NMDA decoy. For pseudobulbar affect. Side effects: dizziness.

20. Ondansetron (4 mg TID) – 5-HT₃ antagonist. Off-label for pseudobulbar affect; anecdotal benefit.

---

Dietary “Molecular” Supplements

Most lack robust PSP-specific trials; dosages reflect general neuroprotective use.

1. Coenzyme Q₁₀ (200 mg daily) – Antioxidant. Supports mitochondrial electron transport; may reduce oxidative stress.

2. Creatine Monohydrate (5 g daily) – Energy reservoir. Buffers cellular ATP, potentially sustaining neural metabolism.

3. Omega-3 Fatty Acids (1,000 mg EPA+DHA daily) – Anti-inflammatory. Modulates membrane fluidity and neuroinflammation.

4. Curcumin (500 mg BID with piperine) – Anti-tau aggregation. Inhibits fibril formation in vitro; poor bioavailability without enhancers.

5. Resveratrol (250 mg daily) – SIRT1 activator. Promotes autophagy of misfolded proteins.

6. Vitamin D₃ (2,000 IU daily) – Neuroimmune modulator. May protect against neurodegeneration via anti-inflammatory effects.

7. Vitamin E (α-Tocopherol) (400 IU daily) – Lipid antioxidant. Scavenges free radicals in neural membranes.

8. Nicotinamide Riboside (250 mg daily) – NAD⁺ precursor. Supports DNA repair and mitochondrial function.

9. Acetyl-L-Carnitine (500 mg BID) – Mitochondrial transporter. Facilitates fatty acid oxidation.

10. Magnesium L-Threonate (2 g daily) – Synaptic modulator. May enhance synaptic plasticity and cognitive function.

---

Advanced-Therapy Drugs (Bisphosphonates, Regenerative, Viscosupplements, Stem-Cell)

These address complications of immobility (osteoporosis) or experimental neurorestoration.

1. Alendronate (70 mg weekly) – Bisphosphonate. Inhibits osteoclast-mediated bone resorption to prevent fractures.

2. Risedronate (35 mg weekly) – Bisphosphonate. Similar mechanism to alendronate; reduces vertebral fractures.

3. Zoledronic Acid (5 mg IV yearly) – Bisphosphonate. Potent antiresorptive for severe osteoporosis.

4. Hyaluronic Acid (Synvisc®) (2 mL IA knee weekly×3) – Viscosupplement. Improves joint lubrication; reduces pain from immobility-related OA.

5. Durolane® (3 mL IA knee single) – Viscosupplement. High-molecular-weight hyaluronan for joint cushioning.

6. Nerve Growth Factor (recombinant) (20 µg intrathecal) – Regenerative. Experimental; promotes cholinergic neuron survival.

7. Granulocyte Macrophage Colony-Stimulating Factor (250 µg SC three times/week) – Regenerative. Stimulates microglial clearance of tau aggregates; pilot data only.

8. Mesenchymal Stem Cells (Autologous) (1×10⁶ cells IT) – Stem cell. Hypothesized to secrete trophic factors; early-phase trial.

9. Induced Pluripotent Stem Cell–Derived Neurons (Experimental dosing) – Stem cell. Under investigation for neuronal replacement; mechanism: direct neuron engraftment.

10. Exendin-4 (GLP-1 agonist) (10 µg daily) – Regenerative. May upregulate neuroprotective pathways; small trials in Parkinsonism pmc.ncbi.nlm.nih.gov.

---

Surgical & Procedural Interventions

Although no standard neurosurgery reverses PSP, selected procedures address specific complications.

1. Percutaneous Endoscopic Gastrostomy (PEG)
   Procedure: Tube placement into stomach for feeding.
   Benefits: Ensures nutrition, reduces aspiration risk.

2. Blepharospasm Myectomy
   Procedure: Resection of orbicularis oculi muscle.
   Benefits: Improves eyelid opening, vision.

3. Strabismus Surgery
   Procedure: Extraocular muscle adjustment.
   Benefits: Reduces diplopia, improves gaze alignment.

4. Deep Brain Stimulation (Experimental)
   Procedure: Electrodes in subthalamic nucleus or pedunculopontine nucleus.
   Benefits: Mixed results on gait and freezing.

5. Ventriculoperitoneal Shunt
   Procedure: CSF diversion in secondary hydrocephalus.
   Benefits: May improve gait/balance if shunt-responsive.

6. Thalamotomy/Pallidotomy
   Procedure: Lesioning motor thalamus or globus pallidus.
   Benefits: May reduce rigidity; limited by disease progression.

7. Botulinum Toxin Injections
   Procedure: Targeted injections for dystonia.
   Benefits: Relieves focal muscle overactivity.

8. Nasojejunal Feeding Tube
   Procedure: Temporary feeding tube through nose.
   Benefits: Short-term nutrition support.

9. Spasticity Release (Tendon Lengthening)
   Procedure: Surgical lengthening of tight tendons (e.g., Achilles).
   Benefits: Improves joint range for transfers.

10. Fracture Fixation
    Procedure: Orthopedic repair of hip or wrist fractures.
    Benefits: Restores mobility after fall-related injuries.

---

Prevention Strategies

While exact causes of PSP are unknown, general neuro-protective and lifestyle measures may help:

1. Head Injury Avoidance (helmets, fall prevention)

2. Regular Aerobic Exercise (150 min/week)

3. Brain-Healthy Diet (Mediterranean-style)

4. Cognitive Stimulation (puzzles, social engagement)

5. Vascular Risk Factor Control (BP, glucose, lipids)

6. Smoking Cessation

7. Moderate Alcohol Intake

8. Adequate Sleep Hygiene (7–9 hours/night)

9. Sunlight Exposure (vitamin D synthesis)

10. Toxin Avoidance (pesticides, heavy metals)

---

When to See a Doctor

• New or worsening unexplained falls, especially backward

• Difficulty looking down, causing reading or walking hazards

• Rapid speech/swallowing changes, choking episodes

• Significant mood or cognitive changes (apathy, impulsivity)

• Poor response to current therapies or intolerable side effects

---

“Do’s” and “Avoid’s”

Do:

1. Use assistive devices (walkers, grab bars)

2. Follow a daily exercise routine

3. Attend multidisciplinary clinics

4. Maintain social and mental activities

5. Practice swallowing safety techniques

6. Monitor bone health (DEXA scans)

7. Keep a medication diary

8. Adapt home for low fall risk

9. Communicate changes early to care team

10. Seek support groups

Avoid:

1. Rapid position changes (orthostatic hypotension risk)

2. Low-lighting environments

3. Wearing loose rugs or slippery shoes

4. High-impact activities without supervision

5. Ignoring nutritional intake

6. Isolating socially

7. Unsupervised swallowing of thin liquids

8. Long periods of immobility

9. Polypharmacy without review

10. Skipping regular follow-up visits

---

Frequently Asked Questions

1. What causes PSP?
   PSP arises from abnormal tau protein accumulation; exact triggers remain unknown en.wikipedia.org.

2. Is PSP hereditary?
   Most cases are sporadic; a MAPT H1 haplotype increases risk but is not determinative en.wikipedia.org.

3. Can levodopa cure PSP?
   No—levodopa offers only modest, short-lived benefit in a minority of patients.

4. How is PSP diagnosed?
   Clinical criteria plus MRI “hummingbird sign” and exclusion of other Parkinson-plus syndromes en.wikipedia.org.

5. Are there any disease-modifying treatments?
   Not yet; several tau-targeting agents are under investigation (e.g., tideglusib, davunetide).

6. What is the role of physical therapy?
   Critical for maintaining mobility, balance and safety; started early for best results pmc.ncbi.nlm.nih.gov.

7. How often should I see my neurologist?
   Every 3–6 months or sooner if symptoms progress rapidly.

8. Can swallowing improve?
   Compensatory strategies and exercises may slow decline; PEG may be needed eventually.

9. Is PSP fatal?
   Yes; median survival is 7–10 years post-diagnosis due to falls, aspiration pneumonia and complications.

10. Will I lose independence?
    Progressive disability is typical; early planning and support can prolong quality of life.

11. Can diet help?
    A balanced, anti-inflammatory diet may support overall brain health.

12. What research is ongoing?
    Trials of tau aggregation inhibitors, immunotherapies and stem-cell approaches are active.

13. How do I cope emotionally?
    Counseling, support groups and mind-body therapies help manage anxiety and depression mayoclinic.org.

14. Can assistive devices prevent falls?
    Properly prescribed walkers and home modifications significantly reduce fall risk nhs.uk.

15. When should hospice be considered?
    When symptom burden outweighs benefit of interventions and quality of life declines substantially.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 07, 2025.